These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 16273803)

  • 1. The CORRONA database.
    Kremer JM
    Clin Exp Rheumatol; 2005; 23(5 Suppl 39):S172-7. PubMed ID: 16273803
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The CORRONA database.
    Kremer JM
    Autoimmun Rev; 2006 Jan; 5(1):46-54. PubMed ID: 16338211
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The CORRONA database.
    Kremer J
    Ann Rheum Dis; 2005 Nov; 64 Suppl 4(Suppl 4):iv37-41. PubMed ID: 16239384
    [No Abstract]   [Full Text] [Related]  

  • 4. Treatment of psoriatic arthritis and rheumatoid arthritis with disease modifying drugs -- comparison of drugs and adverse reactions.
    Helliwell PS; Taylor WJ;
    J Rheumatol; 2008 Mar; 35(3):472-6. PubMed ID: 18203324
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Potential impact of observational cohort studies in Japan on rheumatoid arthritis research and practice.
    Yamanaka H; Tohma S
    Mod Rheumatol; 2006; 16(2):75-6. PubMed ID: 16633925
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Methodological Challenges When Comparing Demographic and Clinical Characteristics of International Observational Registries.
    Verstappen SM; Askling J; Berglind N; Franzen S; Frisell T; Garwood C; Greenberg JD; Holmqvist M; Horne L; Lampl K; Michaud K; Nyberg F; Pappas DA; Reed G; Symmons DP; Tanaka E; Tran TN; Yamanaka H; Ho M
    Arthritis Care Res (Hoboken); 2015 Dec; 67(12):1637-45. PubMed ID: 26201948
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Linkage of a de-identified United States rheumatoid arthritis registry with administrative data to facilitate comparative effectiveness research.
    Curtis JR; Chen L; Bharat A; Delzell E; Greenberg JD; Harrold L; Kremer J; Setoguchi S; Solomon DH; Xie F; Yun H
    Arthritis Care Res (Hoboken); 2014 Dec; 66(12):1790-8. PubMed ID: 24905637
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Real-world anti-tumor necrosis factor treatment in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: cost-effectiveness based on number needed to treat to improve health assessment questionnaire.
    Barra L; Pope JE; Payne M
    J Rheumatol; 2009 Jul; 36(7):1421-8. PubMed ID: 19487267
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An Early Rheumatoid Arthritis Treatment Evaluation Registry (ERATER) in the United States.
    Sokka T; Pincus T
    Clin Exp Rheumatol; 2005; 23(5 Suppl 39):S178-81. PubMed ID: 16273804
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of treatment with biological agents for arthritis in Australia: the Australian Rheumatology Association Database.
    Buchbinder R; March L; Lassere M; Briggs AM; Portek I; Reid C; Meehan A; Henderson L; Wengier L; van den Haak R
    Intern Med J; 2007 Sep; 37(9):591-600. PubMed ID: 17573817
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MonitorNet: the Italian multi-centre observational study aimed at estimating the risk/benefit profile of biologic agents in real-world rheumatology practice.
    Sfriso P; Salaffi F; Montecucco CM; Bombardieri S; Todesco S
    Reumatismo; 2009; 61(2):132-9. PubMed ID: 19633800
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effectiveness of psoriatic arthritis therapies.
    Gladman DD
    Semin Arthritis Rheum; 2003 Aug; 33(1):29-37. PubMed ID: 12920694
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rapid and sustained health utility gain in anti-tumour necrosis factor-treated inflammatory arthritis: observational data during 7 years in southern Sweden.
    Gülfe A; Kristensen LE; Saxne T; Jacobsson LT; Petersson IF; Geborek P
    Ann Rheum Dis; 2010 Feb; 69(2):352-7. PubMed ID: 19282310
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Termination of disease-modifying antirheumatic drugs in rheumatoid arthritis and in psoriatic arthritis. A comparative study of 270 cases.
    Ujfalussy I; Koó E; Seszták M; Gergely P
    Z Rheumatol; 2003 Apr; 62(2):155-60. PubMed ID: 12721703
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effectiveness and retention rates of methotrexate in psoriatic arthritis in comparison with methotrexate-treated patients with rheumatoid arthritis.
    Lie E; van der Heijde D; Uhlig T; Heiberg MS; Koldingsnes W; Rødevand E; Kaufmann C; Mikkelsen K; Kvien TK
    Ann Rheum Dis; 2010 Apr; 69(4):671-6. PubMed ID: 19740904
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rheumatoid arthritis databases in Finland.
    Sokka T
    Clin Exp Rheumatol; 2005; 23(5 Suppl 39):S201-4. PubMed ID: 16273808
    [TBL] [Abstract][Full Text] [Related]  

  • 17. UK consultant rheumatologists' access to biological agents and views on the BSR Biologics Register.
    Kay LJ; Griffiths ID;
    Rheumatology (Oxford); 2006 Nov; 45(11):1376-9. PubMed ID: 17040892
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The efficacy and safety of golimumab in the treatment of arthritis.
    Fleischmann R
    Expert Opin Biol Ther; 2010 Jul; 10(7):1131-43. PubMed ID: 20504106
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Monitoring by rheumatologists for methotrexate-, etanercept-, infliximab-, and anakinra-associated adverse events.
    Yazici Y; Erkan D; Paget SA
    Arthritis Rheum; 2003 Oct; 48(10):2769-72. PubMed ID: 14558081
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The actual role of therapy with traditional disease-modifying antirheumatic drugs in psoriatic arthritis.
    Soriano ER
    J Rheumatol Suppl; 2012 Jul; 89():67-70. PubMed ID: 22751597
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.